Accure Therapeutics

Accure Therapeutics

Accure Therapeutics: Developing innovative medicines to treat CNS disorders.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor

€0.0

round
*

€7.6m

Series A
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR20202021
Revenues00000000
EBITDA00000000
Profit00000000
EV00000000
EV / revenue00.0x00.0x
EV / EBITDA00.0x00.0x
R&D budget00000000

Source: Company filings or news article

More about Accure Therapeutics
Edit

Accure Therapeutics is a research and development pharmaceutical company that focuses on developing new treatments for Central Nervous System (CNS) diseases. The company takes a distinct approach to drug development, utilizing recent advances in neurobiology, neurodegeneration, and neuroinflammation to select relevant targets and develop drugs that can combat neurological diseases. Accure Therapeutics has been awarded a grant by ACCIÓ for their contributions to Parkinson's therapies. This grant demonstrates the company's commitment to finding new treatments for neurological diseases, and their dedication to making a difference in the lives of those affected by these conditions. Accure Therapeutics stands out from other businesses in the same industry by utilizing their understanding of the pathogenesis of brain diseases to develop treatments that can effectively combat neurological diseases. The company is committed to making a difference in the lives of those affected by neurological diseases, and their research and development efforts are focused on finding new treatments for these conditions.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Accure Therapeutics

Edit
Iproteos
ACQUISITION by Accure Therapeutics May 2020
Bionure
ACQUISITION by Accure Therapeutics May 2020